Lirentelimab

DB16728InvestigationalProtein Based Therapies

Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).

Mechanism
Curator reviewed
Also known as
Antolimab · IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS SIALIC ACID-BINDING IG-LIKE LECTIN 8 (SIALOADHESIN FAMILY MEMBER 2, SIGLEC-8, SAF-2))HUMANIZED MOUSE MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (VH (HOMO SAPIENS IGHV3-66*01 (79%) (IGHD)-IGHJ5*01 (91%)/MUS · IMMUNOGLOBULIN G1, ANTI-(HUMAN SIALIC ACID-BINDINGE IG-LIKE LECTIN 8) (HUMAN-MUS MUSCULUS MONOCLONAL AK002 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL AK002 .KAPPA.-CHAIN, DIMER · MONOCLONAL ANTIBODY AK002 · Recombinant humanized, non-fucosylated IgG1 anti-Siglec-8 monoclonal antibody
Code names
AK-002

Resolves to

Compound
UNIISWS48LJU3TCAS2283348-97-8
Targets
Q9NYZ4SIGLEC8

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
14Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lirentelimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In